Food News and Research

RSS

Allos Therapeutics announces results from phase 2 trial of Pralatrexate in peripheral T-cell lymphoma

Allos Therapeutics, Inc. has announced preliminary top line results from PROPEL, the Company's pivotal Phase 2 trial of pralatrexate (PDX) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), at the 50th Annual Meeting of the American Society of Hematology (abstract 261).

8 Dec 2008

Dioxins in Irish pork causes food scare in Britain

A food scare in Britain involving pork from Ireland has forced all major supermarkets to remove all Irish pork products from their shelves because of concerns they may contain toxic dioxins.

8 Dec 2008

Alarm over high lead contamination of Esperance sea food

Alarm over high lead contamination of Esperance sea food. The presence of high concentrations of lead found in fish in a part of Western Australia has prompted a warning to people living in the Esperance area to avoid eating some local seafood.

8 Dec 2008

Trial shows Elitek significantly reduces plasma uric acid levels versus Allopurinol in adults with hematologic cancers at risk for tumor Lysis syndrome

Sanofi-aventis has announced results of a randomized phase III study presented at the 50th Annual Meeting of the American Society of Hematology.

7 Dec 2008

Daiichi Sankyo starts trial of investigational factor Xa inhibitor for atrial fibrillation

Daiichi Sankyo Company, Limited, has announced that it has initiated its pivotal Phase III trial for DU-176b, an investigational oral Factor Xa inhibitor, in patients with atrial fibrillation. DU-176b is being developed solely by Daiichi Sankyo.

7 Dec 2008

New guidelines for tolerable daily intake of melamine

International experts have established a tolerable daily intake (TDI) for melamine, the chemical found recently in contaminated milk products. The TDI is the outcome of a meeting organized by WHO held this week in Ottawa, Canada. The TDI is lower than previous TDIs suggested for melamine by some national food safety authorities.

5 Dec 2008

Zinc key to formation of hospital-acquired infections

Hospital-acquired infections that are resistant to traditional antibiotic treatment have become increasingly common in recent years, confounding health care professionals and killing thousands of Americans.

5 Dec 2008

Discovery of novel prion infectivity in white and brown fat tissues of mice

Prion diseases, also known as transmissible spongiform encephalopathies, are infectious progressive fatal neurodegenerative diseases which affect humans as well as wild and domestic animals.

5 Dec 2008

Interferon as long-term treatment for hepatitis C not effective

Use of the drug interferon as a long-term maintenance strategy to slow the progression of liver disease associated with the hepatitis C virus is ineffective, UT Southwestern Medical Center researchers and their colleagues from nine other institutions have found in a multicenter study.

5 Dec 2008

Moderate alcohol intake boosts amount of omega-3 fatty acids in our body

Moderate alcohol intake is associated with higher levels of omega-3 fatty acids in plasma and red blood cells.

5 Dec 2008

Stereotypical imperfections offer health benefits when it comes to bodies

Having an imperfect body may come with some substantial benefits for some women, according to a new article in the December issue of Current Anthropology.

3 Dec 2008

Study to look at nutrition, ageing and health in Bangladeshi women

The Bangladeshi population is one of the fastest growing ethnic groups within the UK, and are amongst the most socially disadvantaged. A grant of over £500,000 hopes to reduce existing health inequalities and promote healthy, active ageing among Bangladeshi women.

3 Dec 2008

Unstable housing linked to child hunger and poor health

A new study shows that children whose families move frequently or live in overcrowded conditions are more likely to suffer from hunger and poor health than those in stable housing.

3 Dec 2008

NicOx signs agreement with DSM for the commercial manufacture of naproxcinod drug substance

NicOx S.A. has announced it has signed an agreement with DSM for the commercial manufacture and supply of naproxcinod drug substance (or API, active pharmaceutical ingredient).

3 Dec 2008

Horizon Therapeutics announces HZT-501 trials meet primary endpoints

Horizon Therapeutics, Inc. has announced that two pivotal Phase 3 trials evaluating its lead investigational product candidate, HZT 501, met all primary endpoints.

3 Dec 2008

Patient safety compromised with faster drug approvals

With new drugs being reviewed by regulatory agencies and then released onto the market faster than ever before, patients' safety is being compromised, warns a study published on bmj.com.

3 Dec 2008

Generics as good as brand-name drugs when treating heart diseases

Contrary to the perception of some patients and physicians, there is no evidence that brand-name drugs are clinically superior to their generic counterparts, according to an article in the December 3 issue of JAMA, which examined studies comparing the effectiveness of generic vs. brand-name drugs for treating cardiovascular diseases.

3 Dec 2008

Antineoplaston treatment for gliomas granted orphan drug designation by FDA

The Burzynski Research Institute, Inc. (BRI) has announced that its antineoplaston A10 and antineoplaston AS2-1 therapy (ANP) has been granted orphan drug designation by the U.S. Food and Drug Administration ("FDA") for the treatment of gliomas. It is estimated that in 2008 more than 21,000 men and women in the U.S. will be diagnosed with this type of cancer, with prevalence estimated at approximately 84,000 cases.

2 Dec 2008

Cholera outbreaks in Zimbabwe

As of 1 December 2008, the Ministry of Health in Zimbabwe has reported a total of 11 735 cholera cases with 484 deaths since August 2008, affecting all provinces in the country. The overall case fatality rate is 4% but has reached up to 20¨C30% in remote areas. Out of the total number of cases, 50% have been reported from Budiriro, a high density suburb of the capital city, Harare.

2 Dec 2008

New experimental treatment for Tourette's syndrome

The University of Rochester Medical Center (URMC) is leading a multi-center clinical research study of a new experimental treatment for Tourette's syndrome.The study will examine whether or not a drug that alters the chemical activity in the brain can alleviate the symptoms of the disease.

2 Dec 2008